The Penicillins and Streptomycins dosage market in Australia, valued at $260.61 million in 2023, has experienced varied growth rates over the last decade. From 2013 to 2016, the market showed recovery and consistent growth, punctuated by significant spurts in 2015 and 2017. Entering 2019, the market stabilized, albeit with minor fluctuations, before experiencing a notable dip in 2022. Recent data from 2023 indicates a slight rebound. Over the past five years (2018-2023), the market's compound annual growth rate was relatively muted at 1.42%.
Future trends to watch include:
- Potential market consolidation amid increased pharmaceutical regulation.
- Innovations in antibiotic formulations and delivery mechanisms.
- Rising demand due to increased antibiotic resistance.
- Policy shifts in antibiotic use and dispensation.
How does Australia rank in Penicillins and Streptomycins in Dosage Market Size Value?
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | View data |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | View data |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
| 6 | 6 Brazil | 451,970,000 | 2023 | +1.29% | -0.21% | View data |
| 7 | 7 Australia | 260,610,000 | 2023 | +1.79% | +1.42% | |
| 8 | 8 Vietnam | 256,220,000 | 2023 | +4.62% | +6.03% | View data |
| 9 | 9 Canada | 209,600,000 | 2023 | -2.3% | +1.59% | View data |
